Zelgen(SH:688266) 智通财经网·2025-12-21 01:25Group 1 - Suzhou Zelgen Biopharmaceuticals Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1][3] - The company is a comprehensive biopharmaceutical enterprise focused on the discovery of innovative small molecules and biological therapies, with strategic emphasis on oncology, autoimmune diseases, and hemostatic blood disorders [1] - Zelgen Biopharmaceuticals has a product portfolio that includes three marketed drugs: Zepsin, the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zeppin, the first domestically developed innovative JAK3 formulation for treating myelofibrosis; and Zeplin, the only recombinant human thrombin developed and commercialized using recombinant DNA technology in China [1]